Treats locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC)…. Sold as Emrelis. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Telisotuzumab Vedotin-Tllv (sold as Emrelis), first approved May 14, 2025, with 0 new uses approved and 0 published complete response letters.
| Emrelis | Part D | $862K | New | 0 |
| EMRELIS | Part B | $0K | New | 0 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung CancerLung Non-Small Cell Carcinoma · Jonsson Comprehensive Cancer Center | Phase 2 | Recruiting | Jan 7, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| May 14, 2025 | EmrelisBLA 761384 · New molecular entity | Abbvie Inc | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA